BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 24283845)

  • 1. Targeting castration-resistant prostate cancer with monoclonal antibodies and constructs.
    Slovin SF
    Immunotherapy; 2013 Dec; 5(12):1347-55. PubMed ID: 24283845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate-Specific Membrane Antigen-Directed Therapy for Metastatic Castration-Resistant Prostate Cancer.
    Teo MY; Morris MJ
    Cancer J; 2016; 22(5):347-352. PubMed ID: 27749329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal antibody-related drugs for cancer therapy.
    Li GN; Wang SP; Xue X; Qu XJ; Liu HP
    Drug Discov Ther; 2013 Oct; 7(5):178-84. PubMed ID: 24270381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gpnmb/osteoactivin, an attractive target in cancer immunotherapy.
    Zhou LT; Liu FY; Li Y; Peng YM; Liu YH; Li J
    Neoplasma; 2012; 59(1):1-5. PubMed ID: 22017590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [An overview of antibody therapy against cancer].
    Taniguchi H; Imai K
    Nihon Rinsho; 2012 Dec; 70(12):2087-92. PubMed ID: 23259378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on novel monoclonal antibodies and immunoconjugates for the treatment of lymphoproliferative disorders.
    Derby L; Czuczman MS
    Future Oncol; 2011 Aug; 7(8):963-79. PubMed ID: 21823892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular alterations and emerging targets in castration resistant prostate cancer.
    Lorente D; De Bono JS
    Eur J Cancer; 2014 Mar; 50(4):753-64. PubMed ID: 24418724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts.
    Ostermann E; Garin-Chesa P; Heider KH; Kalat M; Lamche H; Puri C; Kerjaschki D; Rettig WJ; Adolf GR
    Clin Cancer Res; 2008 Jul; 14(14):4584-92. PubMed ID: 18628473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoclonal antibodies in therapy of solid tumors.
    Heimann DM; Weiner LM
    Surg Oncol Clin N Am; 2007 Oct; 16(4):775-92, viii. PubMed ID: 18022544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving the efficacy of antibody-based cancer therapies.
    Carter P
    Nat Rev Cancer; 2001 Nov; 1(2):118-29. PubMed ID: 11905803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Castration-resistant prostate cancer: where we stand in 2013 and what urologists should know.
    Heidenreich A; Pfister D; Merseburger A; Bartsch G;
    Eur Urol; 2013 Aug; 64(2):260-5. PubMed ID: 23706522
    [No Abstract]   [Full Text] [Related]  

  • 12. [An overview of antibody-based cancer therapy].
    Miao QF; Shao RG; Zhen YS
    Yao Xue Xue Bao; 2012 Oct; 47(10):1261-8. PubMed ID: 23289136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted alpha-therapy for control of micrometastatic prostate cancer.
    Li Y; Russell PJ; Allen BJ
    Expert Rev Anticancer Ther; 2004 Jun; 4(3):459-68. PubMed ID: 15161444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal antibody therapy for cancer.
    von Mehren M; Adams GP; Weiner LM
    Annu Rev Med; 2003; 54():343-69. PubMed ID: 12525678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long noncoding RNA MALAT-1 is a new potential therapeutic target for castration resistant prostate cancer.
    Ren S; Liu Y; Xu W; Sun Y; Lu J; Wang F; Wei M; Shen J; Hou J; Gao X; Xu C; Huang J; Zhao Y; Sun Y
    J Urol; 2013 Dec; 190(6):2278-87. PubMed ID: 23845456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical studies comparing different bispecific antibodies for redirecting T cell cytotoxicity to extracellular antigens on prostate carcinomas.
    Lum HE; Miller M; Davol PA; Grabert RC; Davis JB; Lum LG
    Anticancer Res; 2005; 25(1A):43-52. PubMed ID: 15816517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The next generation of antibody-drug conjugates comes of age.
    Beck A; Haeuw JF; Wurch T; Goetsch L; Bailly C; Corvaïa N
    Discov Med; 2010 Oct; 10(53):329-39. PubMed ID: 21034674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors.
    Charmsaz S; Scott AM; Boyd AW
    Exp Hematol; 2017 Oct; 54():31-39. PubMed ID: 28751189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting tomoregulin for radioimmunotherapy of prostate cancer.
    Zhao XY; Schneider D; Biroc SL; Parry R; Alicke B; Toy P; Xuan JA; Sakamoto C; Wada K; Schulze M; Müller-Tiemann B; Parry G; Dinter H
    Cancer Res; 2005 Apr; 65(7):2846-53. PubMed ID: 15805286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Monoclonal antibody for cancer treatment].
    Achiwa H; Sato S; Ueda R
    Gan To Kagaku Ryoho; 2002 Apr; 29(4):495-501. PubMed ID: 11977531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.